"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Concept/Terms
Adjuvants, Immunologic- Adjuvants, Immunologic
- Adjuvants, Immunological
- Immunological Adjuvants
- Immunological Adjuvant
- Adjuvant, Immunological
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunopotentiators
- Immunoactivators
- Immunoadjuvants
- Immunostimulants
- Immunologic Adjuvants
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in Harvard Catalyst Profiles by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 1 | 6 |
| 1995 | 3 | 6 | 9 |
| 1996 | 6 | 1 | 7 |
| 1997 | 9 | 5 | 14 |
| 1998 | 7 | 5 | 12 |
| 1999 | 9 | 9 | 18 |
| 2000 | 9 | 8 | 17 |
| 2001 | 9 | 14 | 23 |
| 2002 | 19 | 10 | 29 |
| 2003 | 22 | 16 | 38 |
| 2004 | 17 | 6 | 23 |
| 2005 | 12 | 11 | 23 |
| 2006 | 15 | 8 | 23 |
| 2007 | 10 | 6 | 16 |
| 2008 | 8 | 12 | 20 |
| 2009 | 4 | 12 | 16 |
| 2010 | 7 | 6 | 13 |
| 2011 | 9 | 7 | 16 |
| 2012 | 11 | 14 | 25 |
| 2013 | 8 | 11 | 19 |
| 2014 | 7 | 10 | 17 |
| 2015 | 16 | 8 | 24 |
| 2016 | 12 | 11 | 23 |
| 2017 | 9 | 10 | 19 |
| 2018 | 8 | 8 | 16 |
| 2019 | 7 | 19 | 26 |
| 2020 | 12 | 13 | 25 |
| 2021 | 11 | 14 | 25 |
| 2022 | 2 | 37 | 39 |
| 2023 | 1 | 26 | 27 |
| 2024 | 1 | 6 | 7 |
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research. Clin Cancer Res. 2024 Mar 15; 30(6):1093-1103.
-
Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer. Sci Adv. 2024 Mar 08; 10(10):eadj6380.
-
Risedronate-functionalized manganese-hydroxyapatite amorphous particles: A potent adjuvant for subunit vaccines and cancer immunotherapy. J Control Release. 2024 Mar; 367:13-26.
-
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Feb 17; 403(10427):632-644.
-
Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders. J Mol Biol. 2024 02 15; 436(4):168446.
-
A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer. Eur Urol. 2024 Apr; 85(4):400-402.
-
Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates. Sci Transl Med. 2024 01 03; 16(728):eadd5960.
-
Adjuvant immunotherapy for locally advanced renal cell carcinoma. Expert Opin Biol Ther. 2023 Jul-Dec; 23(12):1265-1275.
-
Micronanoparticled risedronate exhibits potent vaccine adjuvant effects. J Control Release. 2024 Jan; 365:369-383.
-
Percutaneous Intratumoral Immunoadjuvant Gel Increases the Abscopal Effect of Cryoablation for Checkpoint Inhibitor Resistant Cancer. Adv Healthc Mater. 2024 Mar; 13(6):e2301848.